Literature DB >> 22845616

Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics.

M T DelMonte1, J R Bostwick, J D Bess, G W Dalack.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Second-generation antipsychotics (SGAs) play an important role in the pharmacologic management of various psychiatric conditions. Use of these medications has been associated with metabolic complications. Adherence to guideline-recommended monitoring is suboptimal. We evaluated the effect of a computerized physician order entry (CPOE) pop-up alert designed to improve rates of laboratory metabolic monitoring of patients treated with SGAs on a University Hospital inpatient psychiatry unit.
METHODS: A single-centre, retrospective chart review was performed in which patient demographics and SGA drug and laboratory data were extracted from the CPOE database. We assessed the number of orders for appropriate metabolic monitoring data for patients admitted within a 6-month period before or after the alert implementation. RESULTS AND DISCUSSION: Pre-alert (n = 171) and post-alert (n = 157) groups were similar with respect to age, length of stay, sex, race and comorbidities. Following alert implementation, significant increases in monitoring both random (92.4% vs. 100%) and fasting (46.8% vs. 70%) glucose levels as well as random (28.7% vs. 74.5%) and fasting (18.7% vs. 59.9%) lipid panels (all P ≤ 0.001) were observed. The number of patients with both a fasting glucose level and fasting lipid panel available for monitoring increased from 12.9% to 47.8% (P < 0.0001). Significantly more post-alert laboratory orders were submitted at the same time as the SGA drug order (P < 0.0001), suggesting that the alert itself had a direct influence on the ordering of metabolic monitoring labs. WHAT IS NEW AND
CONCLUSIONS: Implementation and use of an electronic pop-up alert in an inpatient psychiatric unit significantly improved rates of ordering fasting blood glucose and lipid levels for inpatients treated with SGAs. Overall rates remain suboptimal, suggesting a need for additional strategies to further improve metabolic monitoring.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22845616     DOI: 10.1111/j.1365-2710.2012.01369.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications.

Authors:  Julie Kreyenbuhl; Lisa B Dixon; Clayton H Brown; Deborah R Medoff; Elizabeth A Klingaman; Li Juan Fang; Stephanie Tapscott; Mary Brighid Walsh
Journal:  Community Ment Health J       Date:  2016-04-09

Review 2.  Interventions to increase access to or uptake of physical health screening in people with severe mental illness: a realist review.

Authors:  Frédérique Lamontagne-Godwin; Caroline Burgess; Sarah Clement; Melanie Gasston-Hales; Carolynn Greene; Anne Manyande; Deborah Taylor; Paul Walters; Elizabeth Barley
Journal:  BMJ Open       Date:  2018-02-10       Impact factor: 2.692

3.  Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness.

Authors:  Christina Mangurian; Grace C Niu; Dean Schillinger; John W Newcomer; James Dilley; Margaret A Handley
Journal:  Implement Sci       Date:  2017-11-14       Impact factor: 7.327

4.  Glucose and Prolactin Monitoring in Children and Adolescents Initiating Antipsychotic Therapy.

Authors:  Yasuyuki Okumura; Masahide Usami; Takashi Okada; Takuya Saito; Hideki Negoro; Noa Tsujii; Junichi Fujita; Junzo Iida
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-06-11       Impact factor: 2.576

5.  The role of pharmacy in the management of cardiometabolic risk, metabolic syndrome and related diseases in severe mental illness: a mixed-methods systematic literature review.

Authors:  Dolly Sud; Eileen Laughton; Robyn McAskill; Eleanor Bradley; Ian Maidment
Journal:  Syst Rev       Date:  2021-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.